Literature DB >> 23490567

Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status.

Dustin B Stephens1, Jennifer R Havens.   

Abstract

OBJECTIVE: Alcohol consumption dramatically increases the risk of liver damage among those with hepatitis C virus (HCV) infection, yet the impact of HCV status disclosure and standard informational counseling on alcohol use among rural drug users remains poorly understood.
METHOD: In this prospective study, 503 rural Appalachian drug users were recruited using respondent-driven sampling. Participants were tested for HCV antibodies, and data on sociodemographic characteristics, lifetime and past-30-day drug and alcohol use, and psychiatric disorders were collected by interviewer-administered questionnaires. A total of 470 participants returned after 6 months for follow-up; however,4 of those had no history of alcohol use, thus leaving a final sample size of 466. Multivariate negative binomial regression was used to determine the effect of disclosure of HCV status and posttest counseling on alcohol consumption at follow-up.
RESULTS: Despite an overall decrease in drinking frequency in the cohort, those who were HCV-positive were drinking at a frequency similar to their HCV-negative counterparts at follow-up, despite posttest counseling informing them of the risks of alcohol use with an HCV diagnosis (adjusted incidence rate ratio = 1.07, 95% CI [0.72, 1.61]). Significant predictors of increased days of alcohol use after 6 months included baseline alcohol use, baseline marijuana use, and meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for antisocial personality disorder. Those using OxyContin at baseline had significantly fewer days of alcohol use at follow-up.
CONCLUSIONS: HCV status disclosure and standard informational counseling alone do not curtail drinking among HCV-positive drug users in the rural setting. Targeted interventions with regard to alcohol use are warranted in order to mitigate the damage of the HCV epidemic.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23490567      PMCID: PMC3602359          DOI: 10.15288/jsad.2013.74.386

Source DB:  PubMed          Journal:  J Stud Alcohol Drugs        ISSN: 1937-1888            Impact factor:   2.582


  72 in total

Review 1.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

2.  Screening for HIV, HBV and HCV markers among drug users in treatment in rural south-east England.

Authors:  J Edeh; P Spalding
Journal:  J Public Health Med       Date:  2000-12

Review 3.  Impact of HCV genetic differences on pathobiology of disease.

Authors:  Maria Ripoli; Valerio Pazienza
Journal:  Expert Rev Anti Infect Ther       Date:  2011-09       Impact factor: 5.091

4.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

Review 5.  Future of hepatitis C therapy: development of direct-acting antivirals.

Authors:  Gregory J Dore; Gail V Matthews; Jürgen Rockstroh
Journal:  Curr Opin HIV AIDS       Date:  2011-11       Impact factor: 4.283

Review 6.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

7.  Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.

Authors:  Bianca Watson; Katherine M Conigrave; Cate Wallace; John B Whitfield; Friedrich Wurst; Paul S Haber
Journal:  Drug Alcohol Rev       Date:  2007-05

8.  Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.

Authors:  R G Simonetti; C Cammà; F Fiorello; M Cottone; M Rapicetta; L Marino; G Fiorentino; A Craxì; A Ciccaglione; R Giuseppetti
Journal:  Ann Intern Med       Date:  1992-01-15       Impact factor: 25.391

9.  Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+.

Authors:  Scott Seronello; Chieri Ito; Takaji Wakita; Jinah Choi
Journal:  J Biol Chem       Date:  2009-11-12       Impact factor: 5.157

10.  Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence.

Authors:  Simon D W Frost; Kimberly C Brouwer; Michelle A Firestone Cruz; Rebeca Ramos; Maria Elena Ramos; Remedios M Lozada; Carlos Magis-Rodriguez; Steffanie A Strathdee
Journal:  J Urban Health       Date:  2006-11       Impact factor: 3.671

View more
  6 in total

1.  Examining the Social Context of Injection Drug Use: Social Proximity to Persons Who Inject Drugs Versus Geographic Proximity to Persons Who Inject Drugs.

Authors:  Abby E Rudolph; April M Young; Jennifer R Havens
Journal:  Am J Epidemiol       Date:  2017-10-15       Impact factor: 4.897

2.  Using Network and Spatial Data to Better Target Overdose Prevention Strategies in Rural Appalachia.

Authors:  Abby E Rudolph; April M Young; Jennifer R Havens
Journal:  J Urban Health       Date:  2019-02       Impact factor: 3.671

3.  The Role of Alcohol on Antiretroviral Therapy Adherence Among Persons Living With HIV in Urban India.

Authors:  Stephen L Schensul; Toan Ha; Jean J Schensul; Melita Vaz; Rajendra Singh; Joseph A Burleson; Kendall Bryant
Journal:  J Stud Alcohol Drugs       Date:  2017-09       Impact factor: 2.582

4.  Continued Substance Use Among People Living With HIV-Hepatitis-C Co-Infection and Receiving Antiretroviral Therapy.

Authors:  Seth C Kalichman; Christopher Washington; Christopher Kegler; Tamar Grebler; Moira O Kalichman; Chauncey Cherry; Lisa Eaton
Journal:  Subst Use Misuse       Date:  2015-11-19       Impact factor: 2.164

Review 5.  Opioid epidemic and liver disease.

Authors:  Elizabeth C Verna; Aaron Schluger; Robert S Brown
Journal:  JHEP Rep       Date:  2019-07-09

Review 6.  A Systematic Review of Published Respondent-Driven Sampling Surveys Collecting Behavioral and Biologic Data.

Authors:  Lisa G Johnston; Avi J Hakim; Samantha Dittrich; Janet Burnett; Evelyn Kim; Richard G White
Journal:  AIDS Behav       Date:  2016-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.